HCM Relative Valuation
HCM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, HCM is overvalued; if below, it's undervalued.
Historical Valuation
HUTCHMED (China) Ltd (HCM) is now in the Undervalued zone, suggesting that its current forward PS ratio of 4.04 is considered Undervalued compared with the five-year average of 20.03. The fair price of HUTCHMED (China) Ltd (HCM) is between 20.58 to 48.42 according to relative valuation methord. Compared to the current price of 17.13 USD , HUTCHMED (China) Ltd is Undervalued By 16.76%.
Relative Value
Fair Zone
20.58-48.42
Current Price：17.13
16.76%
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
18.63
P/B
Median3y
6.88
Median5y
6.38
-0.62
FCF Yield
Median3y
-3.20
Median5y
-3.80
Competitors Valuation Multiple
The average P/S ratio for HCM's competitors is 15.57, providing a benchmark for relative valuation. HUTCHMED (China) Ltd Corp (HCM) exhibits a P/S ratio of 4.04, which is -74.05% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is HUTCHMED (China) Ltd (HCM) currently overvalued or undervalued?
What is HUTCHMED (China) Ltd (HCM) fair value?
How does HCM's valuation metrics compare to the industry average?
What is the current P/B ratio for HUTCHMED (China) Ltd (HCM) as of Jul 17 2025?
What is the current FCF Yield for HUTCHMED (China) Ltd (HCM) as of Jul 17 2025?
What is the current Forward P/E ratio for HUTCHMED (China) Ltd (HCM) as of Jul 17 2025?